Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

NCT02433847•Seoul National University Hospital

Summary

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria

Exclusion Criteria

•Intolerable or hypersensitive to mosapride
•Known Parkinson's ds
•Cardio- or cerebrovascular disease within 3 months
•Malignancy requiring surgery or chemotherapy or radiation within 5 years
•History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation
•Refractory diabetes mellitus/hypertension/thyroid diseases
•Symptomatic heart failure, renal failure, arrhythmia

Key Dates

Start Date

May 1, 2015

Primary Completion Date

April 1, 2016

Completion Date

December 1, 2016

Last Updated

May 5, 2015

Enrollment

ESTIMATED participants

Conditions

Constipated Irritable Bowel SyndromeChronic ConstipationHealthy

Interventions

Mosapride

DRUG

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

RECRUITING

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 5, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

Inclusion Criteria

Exclusion Criteria

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A New Portable Device for Non-invasive Ventilatory Support

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity